Company: MDCXW
Filing Date: 2025-07-30
Form Type: 8-K
Source: 0001062993-25-013266
Chunk: 0

Company: Medicus Pharma Ltd.
Filing Date: 2025-07-30
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events.

On July 29, 2025, Medicus Pharma Ltd. (the "Company") and Deloitte LLP ("Deloitte") entered into an engagement letter (the "Engagement") whereby Deloitte was appointed as the exclusive lead financial adviser to the Company for the purpose of finding one or more partners for an out-licensing transaction for Doxorubicin Microneedle Array ("D-MNA") for the treatment of Basal Cell Carcinoma ("BCC") in adults, whether by license, option, or other agreed structure or mechanism (collectively, a "Transaction"). Under the terms of the Engagement the Company will pay Deloitte a retainer as well as a contingent success fee in the event that a Transaction is consummated.

Forward Looking Statements

Certain information in this Current Report on Form 8-K constitutes "forward-looking statements" under applicable securities laws. "Forward-looking statements" are defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the Company's intention to out-license D-MNA for BCC, whether by a Transaction or otherwise, and the ability of the Company to enter into or to consummate a Transaction. Forward-looking statements are often but not always, identified by the use of such terms as "may", "on track", "aim", "might", "will", "will likely result", "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target" or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company's annual report on form 10-K for the year ended December 31, 2024 (the "Annual Report"), and in the Company's other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company's common shares. Forward-looking statements contained in this Current Report on Form 8-K are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation